Evidence map›Paper›PMID 29599413›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Dipongkor Saha, Hiroaki Wakimoto, Cole W Peters, Slawomir J Antoszczyk, Samuel D Rabkin, Robert L Martuza

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Dipongkor SahaMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.
Hiroaki WakimotoMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.
Cole W PetersMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-7052-1432
Slawomir J AntoszczykMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.
Samuel D RabkinMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts.
Robert L MartuzaMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts. rmartuza@mgh.harvard.edu.
Harvard University · US

Funding

GENETICALLY ENGINEERED VIRUSES FOR BRAIN TUMOR THERAPYR01NS032677 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI MARTUZA, ROBERT L · 1994 to 2022
$9.0M
Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSVR01CA160762 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI RABKIN, SAMUEL DAVID · 2012 to 2023
$3.7M
NCI NIH HHS R01 CA160762NINDS NIH HHS R01 NS032677
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Oncolytic VirotherapyAnimalsAntineoplastic Agents, ImmunologicalAxitinibCell Line, TumorCombined Modality TherapyCytotoxicity, ImmunologicDisease Models, AnimalGenetic VectorsGlioblastomaHumansImmunohistochemistryInterleukin-12MiceNeoplastic Stem CellsNeovascularization, PathologicAntineoplastic Agents, ImmunologicalAxitinibInterleukin-12Protein Kinase InhibitorsReceptors, Vascular Endothelial Growth Factor

Identifiers

PMID29599413
PMCPMC6050085
OpenAlexW2795109290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.